These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17972966)

  • 1. The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand.
    Stehr-Green P; Galloway Y; Kieft C; McNicholas A
    N Z Med J; 2007 Oct; 120(1263):U2746. PubMed ID: 17972966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
    Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
    Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
    Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
    Kelly C; Arnold R; Galloway Y; O'Hallahan J
    Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
    Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
    Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intussusception and rotavirus associated hospitalisation in New Zealand.
    Chen YE; Beasley S; Grimwood K;
    Arch Dis Child; 2005 Oct; 90(10):1077-81. PubMed ID: 15964860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.
    O'Hallahan J; McNicholas A; Galloway Y; O'Leary E; Roseveare C
    N Z Med J; 2009 Mar; 122(1291):48-59. PubMed ID: 19322255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
    Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
    Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hepatitis B resulting in hospitalisation in New Zealand.
    Wilson N; Baker M
    N Z Med J; 1996 Feb; 109(1016):54-5. PubMed ID: 8598939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of vaccine breakthrough cases following MeNZB vaccination.
    McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J
    N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 19. Hospitalisations due to pertussis in New Zealand in the pre-immunisation and mass immunisation eras.
    Somerville RL; Grant CC; Scragg RK; Thomas MG
    J Paediatr Child Health; 2007 Mar; 43(3):147-53. PubMed ID: 17316188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.